Calciphylaxis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Calciphylaxis, or calcific uremic arteriolopathy (CUA), is a rare condition characterized by subcutaneous vascular calcification and cutaneous necrosis. It is frequently observed in individuals with renal failure. This condition is alternatively referred to as metastatic calcinosis cutis and necrotizing or calcifying panniculitis. The precise underlying mechanisms of calciphylaxis remain unclear, which has led to a lack of well-established therapies for its treatment. During the disease, severe pain is a common feature, often accompanied by tactile hypersensitivity, although the pain intensity may vary. Initial skin manifestations can manifest as induration, plaques, nodules, livedo, or purpura. Patients usually exhibit multiple bilateral lesions, with the surrounding skin developing a leather-like texture. These initial lesions progress rapidly into stellate ulcers with a foul odor and the formation of black eschars. Sepsis resulting from these wounds is the leading cause of death. Approximately half of the patients are confined to bed or reliant on wheelchairs, and over 70% require hospitalization due to severe ulcers. There is no FDA-approved treatment for calciphylaxis. However, a 2022 meta-analysis of clinical trials found that intravenous sodium thiosulfate (STS) may help slow the progression of macrovascular calcification in hemodialysis patients.

·       The incidence of Calciphylaxis or calcific uremic arteriolopathy (CUA) ranges from 2 to 4 cases per 100,000 population in the USA.

 

Thelansis’s “Calciphylaxis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Calciphylaxis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Calciphylaxis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Calciphylaxis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Calciphylaxis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Calciphylaxis, Calciphylaxis market outlook, Calciphylaxis competitive landscape, Calciphylaxis market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)